For a hypertensive patient with hypokalemia (serum potassium ~3.6 mmol/L) who cannot safely discontinue beta‑blockers, ACE inhibitors (angiotensin‑converting‑enzyme inhibitors) or angiotensin receptor blockers, and who has chronic kidney disease, how should primary aldosteronism screening be performed and interpreted?

Screening for Primary Aldosteronism in Hypertensive Patients with Hypokalemia, CKD, and Inability to Withdraw ACE/ARB or Beta-Blockers

In hypertensive patients with potassium ≤3.6 mmol/L who cannot safely discontinue beta-blockers, ACE inhibitors, or ARBs, you should first correct the hypokalemia to ≥4.0 mmol/L using potassium chloride supplementation, then proceed with aldosterone-to-renin ratio (ARR) screening while the patient remains on these medications, interpreting results in the context of known drug effects. 1

Approach to Hypokalemia Before Screening

The 2025 Endocrine Society guidelines are explicit: hypokalemia must be corrected before screening because low potassium potently suppresses aldosterone secretion, leading to false-negative results. 1

• Target serum potassium ≥4.0 mmol/L before drawing aldosterone and renin 2
• Use potassium chloride (KCl) only—avoid potassium bicarbonate or potassium-sparing formulations that can interfere with testing 2
• If initial screening is negative with potassium 3.6 mmol/L, repeat testing after potassium correction 1

Critical Technical Point for Potassium Measurement

To avoid spuriously elevated potassium readings, collect blood slowly with syringe and needle (not vacuum tubes), avoid fist clenching, wait ≥5 seconds after tourniquet release, and separate plasma from cells within 30 minutes. 1

Managing Interfering Medications When Withdrawal Is Not Safe

The 2025 guidelines acknowledge that medication withdrawal is often not feasible and provide a pragmatic "no-withdrawal" strategy: 1

For ACE Inhibitors and ARBs (Cannot Withdraw)

• These medications raise renin and lower aldosterone 1
• You can still screen while patients remain on these drugs 1
• Interpretation key: If renin is undetectable despite being on ACE/ARB, this makes PA strongly suspected because these drugs should raise renin 2
• If renin is detectable or ARR is low, this does not exclude PA—you must repeat testing after correcting hypokalemia 2
• Ideally withdraw for 2 weeks if safe, but guidelines explicitly state this is often not feasible 1

For Beta-Blockers (Cannot Withdraw)

• Beta-blockers suppress renin and can cause false-positive ARR 1
• You can still screen, but interpretation depends on aldosterone level: 1
  • If aldosterone >15 ng/dL (416 pmol/L) by immunoassay or >10 ng/dL (277 pmol/L) by LC-MS/MS: PA is likely despite beta-blocker use
  • If aldosterone 10-15 ng/dL (277-416 pmol/L) by immunoassay or 7.5-10 ng/dL (208-277 pmol/L) by LC-MS/MS: Consider false positive from beta-blocker—ideally retest after 2-week withdrawal if safe
  • If aldosterone <10 ng/dL with elevated ARR: High probability of false positive

Preferred Alternative Medications (If Any Substitution Possible)

If blood pressure control allows any medication adjustment, switch to: 1, 2, 3

• Alpha-1 blockers (doxazosin, prazosin)
• Non-dihydropyridine calcium channel blockers (verapamil slow-release, diltiazem)
• Hydralazine

These have minimal interference with ARR testing.

Special Considerations for Chronic Kidney Disease

CKD creates a high false-positive rate for PA screening because: 1

• Renin decreases proportionately to nephron loss (except with renal artery stenosis where renin rises)
• Aldosterone can be elevated in CKD independent of PA
• This combination artificially raises the ARR

CKD-Specific Interpretation Strategy

• Use higher thresholds for suspicion: Require more robust biochemical evidence before proceeding to confirmatory testing 1
• Emphasize clinical context: Resistant hypertension, hypokalemia, or worsening hypertension increase pretest probability 1
• If initial screen is negative but pretest probability is moderate-to-high (hypokalemia and/or resistant hypertension) or renin is suppressed with aldosterone 5-10 ng/dL (138-277 pmol/L), repeat testing on a different day 1

Algorithmic Approach for Your Specific Scenario

Step 1: Correct Hypokalemia

• Supplement with KCl to achieve potassium ≥4.0 mmol/L
• Use proper collection technique for accurate potassium measurement

Step 2: Screen While on Current Medications

• Measure morning aldosterone, renin (PRA or DRC), and ARR
• Patient should be seated, awake >2 hours, unrestricted salt intake (≥5g/day)

Step 3: Interpret Results in Medication Context

If on beta-blocker:

• ARR elevated + aldosterone >15 ng/dL (immunoassay) or >10 ng/dL (LC-MS/MS) → Likely PA, proceed to confirmatory testing
• ARR elevated + aldosterone 10-15 ng/dL (immunoassay) → Possible false positive, repeat if feasible after beta-blocker withdrawal

If on ACE/ARB:

• Undetectable renin despite ACE/ARB → Strongly suspicious for PA
• Detectable renin or low ARR → Does not exclude PA; repeat after potassium correction

If CKD present:

• Apply higher threshold for positive screen
• Emphasize clinical features (resistant hypertension, hypokalemia)

Step 4: Repeat Testing Strategy

• If initial screen negative with interfering factors present → Repeat on different day after potassium correction 1
• If pretest probability moderate-to-high despite negative screen → Repeat testing 1

Step 5: When to Proceed to Confirmatory Testing Skip confirmatory testing and proceed directly to treatment if: 1

• Resistant hypertension or hypertension with hypokalemia AND
• PRA <0.2 ng/mL/h or DRC <2 mU/L AND
• Aldosterone >15 ng/dL (>416 pmol/L) by LC-MS/MS or >20 ng/dL (>554 pmol/L) by immunoassay

This represents "overt biochemical evidence" where confirmatory testing risks false negatives.

Common Pitfalls to Avoid

1. Testing with uncorrected hypokalemia (most common cause of false negatives) 1, 2
2. Dismissing PA because patient is on ACE/ARB with detectable renin—these drugs should raise renin, so even "normal" renin may be inappropriately low 2
3. Over-interpreting elevated ARR in CKD patients—require stronger biochemical and clinical evidence 1
4. Using potassium bicarbonate supplements instead of potassium chloride 2
5. Assuming single negative screen excludes PA when interfering factors present—repeat testing is essential 1

Future Rescreening Indications

Even if initial screening is negative, rescreen if patient develops: 1

• Unexplained worsening or resistant hypertension
• New spontaneous or diuretic-induced hypokalemia
• Atrial fibrillation without structural heart disease or hyperthyroidism